Top

Published in:

21-12-2023 | Trastuzumab | ASO Perspectives

Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

Authors: Monica N. Khattak, DO, Anna M. Chichura, MD, Julie E. Lang, MD

Published in: Annals of Surgical Oncology | Issue 3/2024

Abstract

This ASO perspective reviews the findings of a randomized, phase II clinical trial evaluating adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel and trastuzumab (TH) in stage I human epidermal growth factor receptor 2-positive breast cancer, as reported recently by the ATEMPT trial investigators. Patients treated with T-DM1 had better disease-free survival but did not have fewer treatment toxicities. The T-DM1-treated group had higher rates of treatment discontinuations, therefore long-term follow-up will be required to evaluate survival differences between T-DM1 and TH.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.ADSCrossRefPubMed

Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev. 2018;27(6):619–26.CrossRef

Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.CrossRefPubMed

Mahtani R, Hineman L. Advances in HER2-positive breast cancer: novel therapies and adverse event management. J Adv Practitioner Oncol. 2019;10(2):136.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.CrossRefPubMed

Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. Cancers. 2020;12(8):2081.CrossRefPubMedPubMedCentral

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–41.CrossRefPubMedPubMedCentral

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2019;37(22):1868.CrossRefPubMedPubMedCentral

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Version 4.2023. National Comprehensive Cancer Network; May 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

10.

Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):1–12.CrossRef

11.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.CrossRefPubMedPubMedCentral

12.

Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375–85.CrossRefPubMed

13.

Zhao M, Chen C, Zhang C, Xu X, Tian F, Wu B, et al. Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system. Int J Cardiol. 2023;375:87–93.CrossRefPubMed

14.

Nowsheen S, Viscuse PV, O’Sullivan CC, Sandhu NP, Haddad TC, Blaes A, et al. Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer. Curr Breast Cancer Rep. 2017;9:173–82.CrossRefPubMedPubMedCentral

15.

Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, et al. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardio-Oncology. 2020;6(1):1–9.CrossRef

16.

Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, et al. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022;8(1):18.CrossRefPubMedPubMedCentral

17.

Sella T, Zheng Y, Tayob N, Ruddy KJ, Freedman RA, Dang C, et al. Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022;8(1):127.CrossRefPubMedPubMedCentral

18.

Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, et al. Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033): a phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer. Int J Radiat Oncol Biol Phys. 2022;113(1):117–24.CrossRefPubMed

19.

Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, et al. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021;189(1):103–10.CrossRefPubMed

20.

MagalhãesFilho MA, Aguiar PN Jr, Neves MB, et al. Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (São Paulo). 2022;20:eGS6655.CrossRef

21.

Tolaney SM. ATEMPT 2.0: Adjuvant T-DM1 vs TH. ClinicalTrials.gov identifier: NCT04893109. Updated March 13, 2023. Available at: https://clinicaltrials.gov/study/NCT04893109. Accessed 12 Oct 2023.

22.

Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRef

23.

US FDA. FDA approves ado-trastuzumab emtansine for early breast cancer. Silver Spring, MD: US FDA; 2019.

Title: Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
Authors: Monica N. Khattak, DO
Anna M. Chichura, MD
Julie E. Lang, MD
Publication date: 21-12-2023
Publisher: Springer International Publishing
Keywords: Trastuzumab
Breast Cancer
Breast Cancer
Trastuzumab Emtansine
Published in: Annals of Surgical Oncology / Issue 3/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14766-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

ASO Visual Abstract: Physical Prehabilitation in Patients Who Underwent Major Abdominal Surgery—A Comprehensive Systematic Review and Component Network Meta-analysis Using GRADE and CINeMA Approach

Patients’ Preferences Towards Decision Counseling for Active Surveillance After Neoadjuvant Chemoradiotherapy for Esophageal Cancer

ASO Visual Abstract: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor—A Single-Institution Experience (ID:PARROT Trial)

ASO Visual Abstract: Trends and Determinants of Location of Death Due to Colorectal Cancer in the USA: A Nationwide Study

ASO Visual Abstract: Frail but Resilient: Frailty in Autologous Breast Reconstruction is Associated with Worse Surgical Outcomes but Equivalent Long-Term Patient-Reported Outcomes

ASO Author Reflections: Impact of RAS Mutations on Total Neoadjuvant Therapy Outcomes in Rectal Cancer